As of Feb 27
| -0.04 / -0.49%|
The 14 analysts offering 12-month price forecasts for ARIAD Pharmaceuticals Inc have a median target of 8.00, with a high estimate of 14.00 and a low estimate of 4.50. The median estimate represents a -1.60% decrease from the last price of 8.13.
The current consensus among 15 polled investment analysts is to Hold stock in ARIAD Pharmaceuticals Inc. This rating has held steady since February, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.